” Although the Pfizer COVID-19 protection levels versus omicron after 3 dosages are substantially greater than those seen after 2 dosages, they are less than those observed for delta or other COVID-19 strains,” Tartof said. “Additional doses of existing, adjusted, or novel COVID-19 vaccines may be needed to keep high levels of protection against subsequent waves of COVID-19 triggered by omicron or future variants with similar potential to leave protection.”
Referral: “Durability of BNT162b2 vaccine against healthcare facility and emergency situation department admissions due to the omicron and delta versions in a big health system in the USA: a test-negative case– control study” by Sara Y Tartof, PhD; Jeff M Slezak, MS; Laura Puzniak, PhD; Vennis Hong, MPH; Fagen Xie, PhD; Bradley K Ackerson, MD; Srinivas R Valluri, PhD; Luis Jodar, PhD and John M McLaughlin, PhD, 22 April 2022, The Lancet Respiratory Medicine.DOI: 10.1016/ S2213-2600( 22 )00101-1.
The scientists examined 11,123 health center admissions and emergency situation department visits that did not result in hospitalization for intense breathing infection for this study. The scientists looked at Kaiser Permanente patient records in Southern California from December 1, 2021, to February 6, 2022, when both the delta and omicron variations were flowing in the population.
A new research study published in The Lancet Respiratory Medicine reveals that defense versus the omicron variant degrades with time– even after a 3rd vaccine dose.
Kaiser Permanente finds the Pfizer COVID-19 3rd dosage vaccine protection versus hospitalization from omicron subsides after 3 months.
A research study released on April 22, 2022, in The Lancet Respiratory Medicine reveals that a booster dosage of the Pfizer COVID-19 vaccine supplies strong security, roughly 80% to 90%, in the very first few months versus healthcare facility admissions and emergency situation department sees triggered by the delta and omicron variants of COVID-19. This protection versus omicron deteriorates over time– even after a 3rd vaccine dosage.
” Pfizer BioNTech COVID-19 booster doses substantially improve defense versus omicron, although that security seems to wane after 3 months versus emergency clinic gos to, and even for hospitalization,” said the research studys lead author, Sara Y. Tartof, PhD, an epidemiologist with the Kaiser Permanente Southern California Department of Research & & Evaluation and a faculty member of the Kaiser Permanente Bernard J. Tyson School of Medicine, both in Pasadena. “Trends in waning versus delta-related results were usually comparable to omicron, however with greater effectiveness at each time point than those seen for omicron.”
After 2 dosages of the Pfizer COVID-19 vaccine efficiency against omicron was 41% against healthcare facility admission and 31% against emergency situation department visits at 9 months.
After 3 dosages, effectiveness versus omicron-related hospitalization was 85% at less than 3 months however was up to 55% at 3 months or longer.
Versus emergency situation department visits that did not lead to hospitalization, vaccine effectiveness of 3 doses versus omicron was 77% at less than 3 months but was up to 53% at 3 months or longer.